EA
PTLA

Emerald Advisers’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Emerald Advisers’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500,974
Closed -$12M – 356
2019
Q4 		$12M Sell
500,974
-490
-0.1% -$13.5K 0.51% 86
2019
Q3 		$13.4M Sell
501,464
-35,406
-7% -$994K 0.63% 60
2019
Q2 		$14.6M Buy
536,870
+131,750
+33% +$4.13M 0.59% 75
2019
Q1 		$14.1M Buy
+405,120
New +$11.7M 0.57% 67
2018
Q1 		– Sell
-540,661
Closed -$26.3M – 274
2017
Q4 		$26.3M Buy
540,661
+86,740
+19% +$4.39M 1.01% 32
2017
Q3 		$24.5M Buy
453,921
+9,703
+2% +$570K 1% 35
2017
Q2 		$25M Buy
444,218
+152,225
+52% +$6.1M 1.04% 42
2017
Q1 		$11.4M Sell
291,993
-394,058
-57% -$12.6M 0.47% 86
2016
Q4 		$15.4M Sell
686,051
-57,508
-8% -$1.12M 0.66% 65
2016
Q3 		$16.9M Buy
743,559
+103,115
+16% +$2.42M 0.75% 39
2016
Q2 		$15.1M Buy
640,444
+301,550
+89% +$7.45M 0.73% 43
2016
Q1 		$6.91M Buy
338,894
+123,350
+57% +$3.91M 0.34% 101
2015
Q4 		$11.1M Buy
215,544
+25,156
+13% +$1.22M 0.52% 69
2015
Q3 		$8.11M Sell
190,388
-241,778
-56% -$11.7M 0.42% 78
2015
Q2 		$19.7M Sell
432,166
-734
-0.2% -$29.5K 0.94% 28
2015
Q1 		$15.7M Buy
432,900
+40,151
+10% +$1.38M 0.79% 33
2014
Q4 		$11.1M Buy
392,749
+75,432
+24% +$2.1M 0.59% 54
2014
Q3 		$8.02M Buy
317,317
+27,647
+10% +$728K 0.48% 72
2014
Q2 		$8.45M Sell
289,670
-1,531
-0.5% -$37.1K 0.48% 73
2014
Q1 		$7.54M Buy
291,201
+31,446
+12% +$839K 0.42% 82
2013
Q4 		$6.69M Sell
259,755
-11,820
-4% -$287K 0.36% 95
2013
Q3 		$7.26M Buy
271,575
+4,765
+2% +$113K 0.41% 80
2013
Q2 		$6.56M Buy
+266,810
New +$5.3M 0.4% 82

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Emerald Advisers's PTLA Position: Q1 2020 in Review

Emerald Advisers sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 500,974 shares — an estimated $12M sold.

Emerald Advisers first reported a position in PTLA in Q2 2013 and held it in 23 quarters. The position peaked at $26.3M in Q4 2017. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • Emerald Advisers reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Emerald Advisers sold 500,974 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $12M.
  • Emerald Advisers first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 23 quarters.
  • Emerald Advisers's Portola Pharmaceuticals, Inc. position peaked at $26.3M in Q4 2017.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Emerald Advisers's 13F filing for Q1 2020, filed 30 Apr 2020.